Clinical Trial Update: High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial compares high-dose melphalan with a second stem cell transplant to low-dose cyclophosphamide for patients with relapsed multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Cyclophosphamide (Cytoxan) (cyclophosphamide)
• Melphalan (Alkeran) (melphalan)

Snippet

Sponsor: Leeds Cancer Centre at St. James's University Hospital | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | Status: UNKNOWN